Everyone is chasing signals. Fundz is what comes next.
Everyone gets the same alerts the same morning. Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best few: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
SRXGlobal
Acquired Company
CERo Therapeutics Holdings
Sydney
San FranciscoManufacturingOtherBiotechnologyHealth CareTherapeuticsDescription
SRX Global Inc. has entered into a definitive agreement to acquire CERo Therapeutics, enhancing its position in the oncology space. The merger aims to accelerate the development of CER-1236, an innovative treatment for hematologic malignancies. The transaction is expected to offer CERo enhanced access to capital and operational resources. This acquisition reflects SRX's strategy of investing in companies with long-term value potential.
Fundz sees it the moment SRXGlobal makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired CERo Therapeutics Holdings?
CERo Therapeutics Holdings was acquired by SRXGlobal, based in Sydney. The deal was reported on October 7, 2026. SRXGlobal's business has been in operation for almost 25 years. SRXGlobal is privately held and operates in Manufacturing.
When did SRXGlobal acquire CERo Therapeutics Holdings?
SRXGlobal's acquisition of CERo Therapeutics Holdings was reported on October 7, 2026. SRX Global Inc. has entered into a definitive agreement to acquire CERo Therapeutics, enhancing its position in the oncology space. The merger aims to accelerate the development of CER-1236, an innovative treatment for hematologic malignancies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does CERo Therapeutics Holdings do?
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. It is publicly traded (CERO), operating in Other, and is based in San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.